by European Public Health Alliance | Oct 24, 2019 | Opinion
By Ellen ‘t Hoen LLM PhD, Medicines Law & Policy Patents and other forms of exclusive rights, such as data exclusivity and market exclusivity, are meant to stimulate innovation by rewarding innovators with temporary monopolies over their innovations. These...
by European Public Health Alliance | Oct 24, 2019 | Opinion
By Charlotte Roffiaen, France Assoc Santé In France, shortages of medicines have regularly made the headlines over the past 12 months. Their numbers have indeed skyrocketed since 2008, from 44 to 868 in 2018, with a further 60% increase expected in 2019. In recent...
by European Public Health Alliance | Oct 24, 2019 | Opinion
By the European Cancer Leagues Access to Medicines Taskforce In 2016 European cancer societies decided to leave their comfort zone and join the access to medicines debate. They established the ECL Access to Medicines Task Force which has since then become an...
by European Public Health Alliance | Oct 24, 2019 | Opinion
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer Bringing therapeutic innovation and latest science to patients while keeping patient interests at the centre is a challenging mission. Precision medicine and new approaches to...
by European Public Health Alliance | Oct 8, 2019 | Opinion
The challenges of implementing the WHO Global Code of Practice on the International Recruitment of Health Personnel Between 2013 and 2015, as dissemination partners of the “Health Workers for All and All for Health Workers” project, EPHA, guided by our Dutch members...
by European Public Health Alliance | Oct 8, 2019 | Opinion
The new European Commisison will deliver a new EU Zero Emission Strategy, which needs to lead to significant reductions in air pollution, which is a powerful example of why we need European action to tackle cross-border health challenges. Confronting the climate...
